EcoDrugPlus

Cgmp-Inhibited 3',5'-Cyclic Phosphodiesterase A-Like

Ensembl ID : ENSSMAG00000018400
Gene Symbol: LOC118298916
2 Cross references
215 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSSMAG00000000551
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSSMAG00000020970
Gene Symbol: CACNA1DA
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSSMAG00000018457
Gene Symbol: CACNA1BA
1 Cross references
219 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSSMAG00000021132
Gene Symbol: CACNA1AB
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSSMAG00000016112
Gene Symbol: CACNA2D2A
1 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSSMAG00000010385
Gene Symbol: CACNB1
3 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSSMAG00000000545
Gene Symbol: CACNB3A
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1b

Ensembl ID : ENSSMAG00000028232
Gene Symbol: CACNG1B
2 Cross references
194 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 2a

Ensembl ID : ENSSMAG00000021165
Gene Symbol: CACNG2A
3 Cross references
200 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 3b

Ensembl ID : ENSSMAG00000008337
Gene Symbol: CACNG3B
2 Cross references
179 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSSMAG00000013578
Gene Symbol: CACNG4B
3 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).